Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net (loss) earnings	$ 62.5	$ 653.1
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	1,046.4	691.4
Share-based compensation expense	71.1	66.4
Deferred income tax benefit	(356.6)	(62.2)
Loss from equity method investments	85.5	77.5
Other non-cash items	226.1	206.2
Litigation settlements, net	558.6	19.1
Write off of financing fees	35.8	0.0
Losses on acquisition-related foreign currency derivatives	128.6	0.0
Changes in operating assets and liabilities:
Accounts receivable	183.3	(54.3)
Inventories	(336.7)	(288.4)
Trade accounts payable	(45.0)	242.5
Income taxes	51.3	(178.5)
Other operating assets and liabilities, net	(13.2)	(16.3)
Net cash provided by operating activities	1,697.7	1,356.5
Cash flows from investing activities:
Capital expenditures	(239.5)	(207.3)
Change in restricted cash	(50.5)	25.9
Purchase of marketable securities	(22.8)	(59.1)
Proceeds from sale of marketable securities	15.8	29.4
Cash paid for acquisitions, net	(6,151.7)	0.0
Cash paid for Meda's unconditional deferred payment	(308.0)	0.0
Settlement of acquisition-related foreign currency derivatives	(128.6)	0.0
Payments for product rights and other, net	(196.3)	(428.2)
Net cash used in investing activities	(7,081.6)	(639.3)
Cash flows from financing activities:
Payments of financing fees	(95.3)	(114.7)
Change in short-term borrowings, net	48.6	(329.7)
Proceeds from convertible note hedge	0.0	1,970.8
Proceeds from issuance of long-term debt	6,519.8	2,390.0
Payments of long-term debt	(1,067.0)	(4,334.1)
Proceeds from exercise of stock options	11.1	92.8
Taxes paid related to net share settlement of equity awards	(12.9)	(31.7)
Contingent consideration payments	(15.5)	0.0
Acquisition of noncontrolling interest	(1.0)	(11.7)
Other items, net	1.6	49.6
Net cash provided by (used in) financing activities	5,389.4	(318.7)
Effect on cash of changes in exchange rates	15.1	(37.0)
Net increase in cash and cash equivalents	20.6	361.5
Cash and cash equivalents — beginning of period	1,236.0	225.5
Cash and cash equivalents — end of period	1,256.6	587.0
Non-cash transactions:
Ordinary shares issued for acquisition	$ 1,281.7	$ 6,305.8